We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App





Hologic Aptima SARS-CoV-2 Assay’s FDA EUA Amended to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling

By LabMedica International staff writers
Posted on 08 Oct 2020
Print article
Image: Aptima® SARS-CoV-2 Assay (Photo courtesy of Hologic, Inc.)
Image: Aptima® SARS-CoV-2 Assay (Photo courtesy of Hologic, Inc.)
Hologic, Inc.’s (Marlborough, MA, USA) Aptima SARS-CoV-2 assay, which had initially received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) in May, has now been authorized for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.

In addition, the FDA has authorized the company’s pooling protocol for symptomatic testing with the Aptima SARS-CoV-2 assay. The authorization follows a recent announcement of similar claims for Hologic’s Panther Fusion SARS-CoV-2 assay. The asymptomatic screening claim is based on available analytical data, including results published in a recent FDA report, as well as Hologic’s commitment to submit results from a clinical evaluation currently in progress. The FDA report showed that Hologic’s assays are the most analytically sensitive of the fully automated, high-throughput molecular tests on the market. The Aptima and Panther Fusion SARS-CoV-2 tests run on Hologic’s fully automated Panther and Panther Fusion systems, respectively, each of which can provide initial results in approximately three hours and process more than 1,000 coronavirus tests in 24 hours.

“For many years, molecular tests – tests that directly detect the genetic material of pathogens – have been recognized as the gold standard for infectious disease diagnostics,” said Kevin Thornal, president of the Diagnostic Solutions Division at Hologic. “They remain the most sensitive and accurate available options, which is particularly important when screening individuals with no symptoms or known contact with infected people, and therefore no clues about their infectious state."



Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Schematic view of the placenta (Photo courtesy of Wikimedia Commons)

Analysis of Placental Cell Free DNA and RNA Predicts Gestational Complications

A recent paper revealed that circulating cell-free nucleic acids (DNA and RNA) shed from the placenta into the mother's blood during the first trimester of pregnancy could be used to predict potentially... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.